NASDAQ 100 % ()
FTSE 100 % ()
DOLLAR INDEX % ()
BTC/USD % ()
EUR/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()
CRUDE OIL % ()

MRK

Merck & Company Inc. (new) New York Stock Exchange
$83.38
Open: $0.00 High: $0.00 Low: $0.00 Close: $0.00
Range: 0 - 0
Volume: 0
Market: Closed
Powered by Finage Stock APIDelayed data
MRK
Merck & Company Inc. (new) 2000 Galloping Hill Road Kenilworth NJ, 7033 http://www.merck.com
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.
  • CEO: Kenneth C. Frazier
  • Employees: 69,000
  • Sector: Healthcare
  • Industry: Drug Manufacturers
MRK News
Latest news about the MRK
  • Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

    Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

    View More →
  • Merck (MRK) Stock Moves -0.21%: What You Should Know

    Merck (MRK) closed at $82.17 in the latest trading session, marking a -0.21% move from the prior day.

    View More →
  • Beigene Stock Breaks Out To Record High On Cancer Drug OK In China

    Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.

    View More →
  • Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA

    Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.

    View More →
  • Bristol Myers Looks to Its Drug Pipeline to Turbocharge Growth

    The drugmaker expects its current pipeline of drugs could generate $25 billion in annual revenue and sees opportunities for more acquisitions.

    View More →
  • Moderna's Coronavirus Vaccine Secures Swiss Regulatory Approval

    Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate mRNA-1273 gained another regulatory approval Tuesday. Separately, the company also announced a high-profile executive appointment.Sixth Approval Secured: Cambridge, Massachusetts-based Moderna said Tuesday that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized its vaccine in Switzerland.The authorization was issued according to the "ordinary approvals" procedure, and was based on a rolling submission of data and the totality of scientific evidence shared by the company, Moderna said.Related Link: The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off The Swiss government has secured 7.5 million doses of mRNA-1273. Moderna expects to begin delivery of the first doses next week.The company's vaccine has already been conditionally approved in the U.S., Canada, Israel, U.K. and European Union. Moderna Strengthens Executive Team: The company announced the appointment of Jose M. Vega as its chief safety officer effective Jan. 11. He will report to Moderna's chief medical officer Tal Zaks.Vega was most recently with Merck & Co., Inc. (NYSE: MRK), where he was heading the Global Clinical Safety and Pharmacovigilance organization, and was also functioning as chief safety officer for Merck Research Labs.In premarket trading Tuesday, Moderna shares were edging up 0.2% to $117.50.Related Link: The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue See more from Benzinga * Click here for options trades from Benzinga * The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off * Moderna Hires Amgen Executive As Chief Commercial Officer To Bolster Vaccine Marketing(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) * 10X Genomics Inc (NASDAQ: TXG) * AbbVie Inc (NYSE: (ABBV) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) * AtriCure Inc. (NASDAQ: ATRC) (reacted to the company's preliminary fourth-quarter results) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * Biodesix Inc (NASDAQ: BDSX) * C4 Therapeutics Inc (NASDAQ: CCCC) * CareDx Inc (NASDAQ: CDNA) (announced preliminary fourth-quarter results) * Celsius Holdings, Inc. (NASDAQ: CELH) * Chimerix Inc (NASDAQ: CMRX) * Curis, Inc. (NASDAQ: CRIS) * Dyne Therapeutics Inc (NASDAQ: DYN) (announced positive preclinical data from its myotonic dystrophy type 1 program) * Edap Tms SA (NASDAQ: EDAP) * Eli Lilly And Co (NYSE: LLY) (announced positive data from midphase study of its investigational asset in treating early symptomatic Alzheimer's) * ESSA Pharma Inc (NASDAQ: EPIX) * EXACT Sciences Corporation (NASDAQ: EXAS) (reacted to preliminary fourth-quarter results) * Eyenovia Inc (NASDAQ: EYEN) * Guardant Health Inc (NASDAQ: GH) * Johnson & Johnson (NYSE: JNJ) * Kaleido Biosciences Inc (NASDAQ: KLDO) * Oxford Immunotec Global PLC (NASDAQ: OXFD) * Pacira Biosciences Inc (NASDAQ: PCRX) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Syneos Health Inc (NASDAQ: SYNH) * Theratechnologies Inc (NASDAQ: THTX) * Twist Bioscience Corp (NASDAQ: TWST) * United Therapeutics Corporation (NASDAQ: UTHR) * Vascular Biogenics Ltd (NASDAQ: VBLT) * Xencor Inc (NASDAQ: XNCR)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Jan. 11) * AbCellera Biologics Inc (NASDAQ: ABCL)Stocks In Focus T2 Biosystems' Molecular Diagnostic Test Capable Of Detecting Multiple Coronavirus Variants T2 Biosystems Inc (NASDAQ: TTOO) announced that its T2SARS-CoV-2 Panel, a molecular diagnostic test that detects SARS-CoV-2, is capable of detecting multiple variants of the SARS-CoV-2 virus most recently identified in the U.K., South Africa and the U.S."I'm proud that we can confidently say, after extensive analysis, that our T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95 percent and specificity of 100 percent, can continue to help impact lives by detecting multiple variants of the SARS-CoV-2 virus," T2 Biosystems President and CEO John Sperzel said in a statement. The stock was up 39.38% premarket Tuesday to $2.23.GSK, Vir To Begin COVID-19 Antibody Study In Patients With Mild-To-Moderate Infection GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild-to-moderate COVID-19 in a Phase 1b/2a clinical trial.VIR-7832 is a neutralizing COVID-19 antibody that showed promising results in preclinical studies. It enhanced the ability to clear infected cells and possessed potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection.The trial is expected to begin in the first quarter at multiple sites across the U.K.GlaxoSmithKline shares were down 0.53% premarket at $37.73. Roche To Present Positive Results For Late-Stage Kidney Cancer Combo Therapy Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced updated overall survival data from the Phase 3 IMbrave150 study evaluating Tecentriq in combination with Avastin, compared with Bayer AG's (OTC: BAYRY) Nexavar, in people with unresectable hepatocellular carcinoma.The data showed that after a median follow-up of 15.6 months, Roche's combo reduced the risk of death by 34%, with a median overall survival of 19.2 months compared with 13.4 months for Nexavar."These results show that Tecentriq in combination with Avastin provides the longest survival that we've ever seen in a front-line Phase III study in unresectable HCC," said Levi Garraway, Roche's chief medical officer.Roche will present the data at the ASCO Gastrointestinal Cancers Symposium from 3:30-4:15 p.m. Sunday.Novartis In-Licenses BeiGene's Cancer Drug For $650M Novartis AG (NYSE: NVS) and Beigene Ltd (NASDAQ: BGNE) signed a strategic collaboration agreement to in-license BeiGene's tislelizumab in major markets outside of China. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.The agreement provides for Novartis obtaining the development and commercialization rights to tislelizumab in the U.S., Canada, Mexico, the EU, U.K., Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan in exchange for an upfront payment of $650 million plus royalties and milestone payments. BeiGene will retain the rights to tislelizumab in China and other countries. The transaction has been approved by the boards of both companies.BeiGene shares were up 2.12% premarket at $284.84. Amneal To Buy Specialty Pharms Company Kashiv Amneal Pharmaceuticals Inc (NYSE: AMRX) announced an agreement to acquire a 98% interest in Kashiv Specialty Pharmaceuticals for a cash payment of $70 million at closing and a payment of $30 million at the one-year anniversary point of the deal. The company is engaged in the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.Kashiv is also eligible to receive up to an additional $8 million in contingent payments upon the achievement of certain regulatory milestones. In addition to the foregoing contingent payments, Amneal has agreed to pay Kashiv certain royalty payments equal to an escalating percentage of aggregate annual net sales for certain pharmaceutical products.Related Link: The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off IGM In-Licenses Cancer Drug From Sweden's Medivir For Up To $352.5M IGM Biosciences Inc (NASDAQ: IGMS) announced that it has entered into an exclusive license agreement with Medivir AB through which IGM will receive global, exclusive development and commercialization rights for the cancer drug birinapant.The combination of IGM-8444, an IgM antibody targeting death receptor 5 being developed by IGM, and birinapant has been shown to enhance anti-tumor activity preclinically.IGM will pay $1 million upon signing the agreement, followed by an additional $1.5 million when birinapant is included by IGM in clinical Phase I studies. The terms of the agreement also entitle Medivir to receive development and regulatory milestone payments up to a total of approximately $350 million, plus tiered royalties from the mid-single digits up to mid-teens on net sales.Adaptive Biotechnologies, AstraZeneca To Collaborate On Mapping Immune Response To Cancer Antigens Adaptive Biotechnologies Corp (NASDAQ: ADPT) announced a translational collaboration with AstraZeneca plc (NASDAQ: AZN) to investigate the use of immunoSEQ T-MAP -- a product that combines the sequencing and mapping capabilities of Adaptive's proprietary immune medicine platform to map T-cell receptors to antigens -- across AstraZeneca's oncology portfolio.Adaptive stands to receive quarterly payments plus sequencing and data mapping fees. In addition, AstraZeneca has an option to enter into a separate agreement with Adaptive for the development and commercialization of a companion diagnostic or therapeutic application based on T-MAP data.La Jolla Licenses European Rights To 2 Drugs For Up To $122M La Jolla Pharmaceutical Company (NASDAQ: LJPC) announced an exclusive licensing agreement with PAION AG for Giapreza and Xerava in the European Economic Area, the U.K. and Switzerland for an upfront cash payment of $22.5 million and potential commercial milestone payments of up to $109.5 million. La Jolla will also receive double-digit tiered royalty payments based on net sales.La Jolla shares were up 61.42% to $6.36 in premarket trading Tuesday.Merck's Pneumococcal Conjugate Vaccine Accepted For Priority ReviewMerck & Co., Inc. (NYSE: MRK) said the FDA accepted for priority review a BLA for V114, its investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 and older. The FDA set a PDUFA goal date of July 18.In premarket trading Tuesday, Merck shares were adding 0.12% to $85.10.Pre-Announcements GenMark Diagnostics, Inc (NASDAQ: GNMK) preannounced full-year 2020 revenues of about $171 million, up 95% year-over-year, with ePlex revenues climbing 155% to $152 million.Fourth-quarter revenues are expected at $50 million, an 84% increase from a year-ago. Analysts, on average, estimate full-year revenues of $167.48 million and fourth-quarter revenues of $45.87 million.The stock was up 5.3% premarket at $16.30. Orthopediatrics Corp (NASDAQ: KIDS) announced preliminary fourth-quarter revenues of $21.7 million, up 14% year-over-year, and full-year revenues $73.8 million, representing annual growth of 2%. The consensus estimates call for revenues of $20.31 million for the quarter and $72.46 million for the full year.Offerings RedHill Biopharma Ltd (NASDAQ: RDHL) said it has entered into an underwriting agreement with H.C. Wainwright & Co. for the purchase on a firm commitment basis of 1.28 million ADSs at a price of $7.84 per ADS. The closing of the offering is expected to occur on or about Jan. 14, subject to satisfaction of customary closing conditions.The stock was down 7.58% premarket at $8.05. Theratechnologies entered into an agreement with Mackie Research Capital as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, pursuant to which the underwriters have agreed to purchase, on a bought-deal basis, 14.55 million units of the company for aggregate gross proceeds of $40 million at a price of $2.75 per unit.The stock was declining 5.66% premarket to $3. MediciNova, Inc. (NASDAQ: MNOV) said it has entered into a securities purchase agreement pursuant to which MediciNova has agreed to issue $20 million in shares of its common stock to 3D Opportunity Master Fund, a fund managed by 3D Investment Partners, in a private placement transaction.MediciNova intends to use the proceeds received from the private placement primarily for its clinical programs.Polarityte Inc (NASDAQ: PTE) said it has entered into a securities purchase agreement with a single, health care-dedicated institutional investor providing for the purchase and sale of 9.09 million shares of its common stock, or pre-funded warrants to purchase common stock in lieu thereof, and accompanying warrants to purchase up to 9.09 million shares of common stock.The stock eased 5.62% to $1.18 in premarket trading Tuesday.Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off * The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older

    US FDA Accepts for Priority Review the Biologics License Application for V114 for Use in Adults 18 Years of Age and Older

    View More →
  • Sanofi (SNY) to Acquire Kymab to Boost Immunology Presence

    Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.

    View More →
  • The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx

    The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx

    View More →
  • 15 Best Dividend Stocks with Upside Potential

    In this article, we present to you the 15 best dividend stocks with upside potential. If you’re in a hurry, click to skip ahead and jump to the 5 Best Dividend Stocks with Upside Potential. Dividend stocks are companies that pay out regular dividends. Dividend stocks are usually well-established companies with a track record of […]

    View More →
  • Merck (MRK) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Merck (MRK) closed at $83.03, marking a -1.18% move from the previous day.

    View More →
  • Top Analyst Reports for Coca-Cola, Merck & Royal Dutch Shell

    Top Analyst Reports for Coca-Cola, Merck & Royal Dutch Shell

    View More →
  • 3 Low Forward Price-Earnings Ratio Stock Picks

    Their forward-looking valuations are trading below the S&P; 500's historical average

    View More →
  • Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4

    Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4

    View More →
  • How Many Merck & Co., Inc. (NYSE:MRK) Shares Do Institutions Own?

    Every investor in Merck & Co., Inc. ( NYSE:MRK ) should be aware of the most powerful shareholder groups. Institutions...

    View More →
  • Dow Jones Jumps 600 Points: Bet on 4 Momentum Stocks to Win Big

    Here we discuss four momentum-focused top-ranked Dow Jones stocks -- JPM, GS, PG and MRK -- that are well poised to flourish in 2021 on strong fundamentals.

    View More →
  • Roche's (RHHBY) Immunotherapy Gets Breakthrough Therapy Status

    Roche's (RHHBY) tiragolumab in combination with Tecentriq wins Breakthrough Therapy designation for the first-line treatment of patients with metastatic non-small cell lung cancer.

    View More →
  • Merck Stock Is Deeply Undervalued, Says Citi. It Could Surge in 2021.

    Merck stock slumped 11% last year, lagging both the pharma sector and broader market. Citi analyst Andrew Baum rates shares at Buy and sees them rising 31%.

    View More →
  • Got $1,000? These 2 Top Stocks Can Make You Rich

    If you are looking for reasonably priced stocks poised for a solid long-term growth trajectory in 2021, then you're at the right place. It will take only $1,000 in disposable cash, and you could get rich by investing in these two top-notch healthcare stocks. AbbVie (NYSE: ABBV) offers a solid combination of robust growth prospects and steady income.

    View More →